A Framework for Consistent Treatment Admissions

Ready to See Results?

From strategy to execution, we turn underperforming campaigns into measurable wins. Let’s put our expertise to work for your business.

Key Takeaways

Treat admissions as a four-stage pipeline—access, intake speed, clinical fit, and retention design—because adding referral volume to a leaky pipeline produces discharges, not completed episodes.
Median days-to-admission is the highest-leverage controllable metric, since delayed entry significantly reduces retention through the first four sessions ⁹and exposes callback, verification, and scheduling lags.
Replace cost per admission with cost per retained admission by dividing CPA by retention at a meaningful window, using the FDA’s six-month reference point ⁷as the benchmark.
Focus next on instrumenting each stage by source, payer, and site: referral-to-contact within 24 hours, level-of-care match rate, and 30/90/180-day retention paired with a functional measure ¹⁰.

The Gap Between Admission and Completion Is the Real Operating Problem

In 2022, single state agencies reported 1,498,034 substance use treatment admissions and 1,394,138 discharges nationally ². This near-equal volume of admissions and discharges highlights a critical operating problem: the constraint is not the number of people entering treatment, but rather the efficiency of the system in moving individuals from initial contact to a clinically meaningful completion. The throughput, not the admissions volume, is the bottleneck.

The demographic profile of admitted patients further emphasizes this point. In 2022, 17.7% of admissions were experiencing homelessness and 43.7% were unemployed at intake ². This indicates that programs are serving a population facing significant practical barriers, such as unstable housing or lack of transportation, which directly impact their ability to remain in treatment beyond the initial weeks.

For operators, “consistent admissions” must therefore mean more than just filling beds for a single cycle. It requires a robust system that can quickly convert referrals into admissions, ensure appropriate clinical placement from the outset, and effectively retain patients past the critical early drop-off period where most attrition occurs. This framework views admissions as a four-stage pipeline—access, intake speed, clinical fit, and retention design—each stage being measurable against established clinical benchmarks. The core idea is that programs that effectively instrument these four stages achieve predictable bed occupancy, unlike those that simply increase lead generation without addressing pipeline inefficiencies.

Admissions as a Four-Stage Pipeline

Why Marketing Volume Cannot Repair a Broken Pipeline

Injecting more referrals into a pipeline that consistently loses patients between assessment and the fourth session will not increase completed treatment episodes; it will only increase discharges. Research directly supports this, showing that delayed treatment entry significantly reduces retention through the first four treatment sessions ⁹. This means the time between a patient’s first contact and their admission is a clinical variable, not merely an administrative one.

Programs that invest in paid search or referral partnerships while maintaining a lengthy intake lag are essentially paying for patient drop-off. Leads convert at the top of the pipeline but exit before the third week. While the “cost per admission” might appear acceptable on a marketing dashboard, the “cost per retained admission,” when calculated against the actual completion rate, reveals a much less favorable picture.

Patient engagement is not a passive phenomenon dependent solely on patient motivation. A 2025 review of engagement and retention practices emphasizes that providers must proactively engage individuals and design services to enhance retention, rather than waiting for motivation to spontaneously appear ¹⁶. Therefore, increasing volume only magnifies the existing pipeline’s performance: if the pipeline is inefficient, more volume will result in more patients being lost.

The Four Controllable Stages: Access, Intake Speed, Clinical Fit, Retention Design

The admissions pipeline is structured into four distinct stages, each featuring a controllable input and a measurable output:

Access: Encompasses how patients initially connect with the program, including screening pathways, referral handoffs, telehealth induction, and network adequacy. The SAMHSA SBIRT model, for instance, outlines a public health approach combining screening, brief intervention, and referral to treatment for individuals at risk of or with substance use disorders ¹. The measurable output for this stage is the referral-to-contact rate.
Intake speed: Measures the duration between a patient’s first contact and their clinical admission. This stage is critical because delayed entry is known to negatively impact early retention ⁹. The key measurable output here is days-to-admission.
Clinical fit: Involves matching patients to the appropriate level of care, assessing their readiness for change, and establishing a collaborative relationship during initial sessions. SAMHSA’s guidance on treatment entry recommends assessing readiness, fostering collaboration, identifying barriers, and placing clients in the least intensive effective level of care ¹⁷. The measurable output is the level-of-care match rate.
Retention design: Covers all interventions post-admission, such as barrier reduction, medication access, and peer support, which influence whether patients remain in treatment for extended periods. The measurable outputs are 30-, 90-, and 180-day retention rates.

Each stage presents unique challenges and requires specific instrumentation to monitor and improve performance. The subsequent sections will detail each stage.

Visualize the four-stage admissions pipeline framework that organizes the entire article, showing each stage's controllable input and measurable output as described in the section

Stage One: Access and Referral Infrastructure

Screening Pathways and Referral Handoffs

Access to treatment often begins before a patient directly contacts an admissions line, typically at a screening point such as an emergency department, primary care visit, or community health event. The SAMHSA SBIRT model, which advocates for screening, brief intervention, and referral to treatment, assumes that these referrals successfully lead to treatment ¹. However, operationally, many referrals do not result in actual clinical contact.

A common failure point is the delay between screening and the first clinical interaction. A referral sent via fax to a general inbox, left unaddressed overnight, and followed up days later is effectively a lost referral. Programs that view referral source relationships as purely sales-driven, rather than as clinical workflows, often only discover these inefficiencies when they audit the actual conversion rate of screened patients to intake.

To instrument this stage, operators should track the percentage of documented referrals from each upstream source that result in a live clinical contact within 24 hours. This metric, segmented by source, reveals which referral relationships are genuinely effective and which are merely nominal.

Telehealth Induction as Documented Access Infrastructure

Telehealth has evolved beyond a temporary solution into a proven access infrastructure with measurable positive effects on retention. Operators who do not fully integrate telehealth are limiting their pipeline’s potential. A Medicaid-based study, summarized by NIDA, compared buprenorphine initiation in Kentucky and Ohio. In Kentucky, 48% of patients initiating buprenorphine via telehealth remained in treatment for 90 days, compared to 44% in non-telehealth settings. In Ohio, these figures were 32% versus 28% ³. While the absolute differences are modest, their consistent direction across two distinct state Medicaid populations, particularly at the stage of highest attrition, underscores telehealth’s value.

The primary mechanism behind this improvement is the reduction of access friction. Patients who can complete induction from a phone or laptop bypass common barriers like transportation, childcare, and scheduling, which often derail treatment engagement in the first week. CMS has recognized telehealth access as a key lever, alongside workforce development and reimbursement design, for expanding treatment access in high-need areas ⁴.

For operators, the critical question is whether telehealth induction functions as a genuine, same-day intake pathway or if it is merely an advertised option that routes through the same multi-day callback queues as other services. A telehealth option that takes three days to schedule will not yield the retention benefits observed in the Medicaid study.

Network Adequacy, Prior Authorization, and Workforce Levers

Access can also be hindered by structural issues beyond the immediate clinical encounter. CMS guidance for expanding OUD treatment in high-need areas identifies network adequacy, reimbursement policies, managed care strategies, and provider stigma as crucial factors determining whether referrals successfully convert into admissions ⁴. This guidance specifically highlights geographic proximity and wait-time standards as concrete measures of network adequacy.

Prior authorization is a particularly visible operational bottleneck. A patient who completes intake but then waits several days for medication authorization faces an elevated risk of disengagement. This delay falls within the same controllable window where days-to-admission already predicts patient drop-off. Medicaid guidance confirms that all state programs cover some form of buprenorphine and extended-release naltrexone, along with counseling and behavioral therapies ⁵. The issue is not coverage itself, but the speed of processing within that coverage.

While operators cannot dictate payer rules, they can measure the median time from admission decision to the first medication dose, segmented by payer. Outliers in this metric should be treated as workflow problems within the program, rather than solely as external payer issues.

Stage Two: Days-to-Admission as the Highest-Leverage Metric

Among all controllable inputs in the admissions pipeline, the interval between a patient’s first contact and their clinical admission possesses the clearest evidence base for its impact. A peer-reviewed study on individuals seeking treatment for alcohol and drug disorders demonstrated that delayed treatment entry significantly reduced retention through the first four treatment sessions ⁹. The reason is straightforward: patient motivation can wane, life circumstances intervene, and the window of readiness for treatment often closes faster than intake workflows account for.

This stage represents an area where operators have significant control. Unlike external factors such as payer regulations or workforce shortages, days-to-admission is an internal process metric. It can be precisely measured from the timestamp of the initial contact to the timestamp of clinical admission, and further segmented by referral source, payer, and level of care.

Typically, three operational failure points contribute to this lag:

Callback latency, which is the time an inbound contact waits for a return call from an admissions coordinator;
Verification of benefits, the time required to confirm insurance before a bed offer is made;
Scheduling, the duration between a bed offer and the patient’s actual arrival or login.

Each of these points can be timestamped and audited for efficiency.

The 2025 engagement review reinforces this operational perspective, asserting that providers must proactively engage individuals in care and design services to increase retention ¹⁶. This means the days between contact and admission should not be viewed as inert administrative time; they are critical clinical time that directly predicts whether a patient will attend their fourth session.

Stage Three: Clinical Fit and Level-of-Care Matching

Achieving speed without ensuring clinical fit often leads to patient churn. An admission is technically successful but clinically flawed if a patient is placed in residential treatment when intensive outpatient care would have been more appropriate, or in standard outpatient care when withdrawal management was indicated. The SAMHSA treatment entry chapter clearly outlines the necessary sequence: assess readiness for change, build a collaborative relationship, identify barriers, and match clients to the least intensive effective level of care ¹⁷.

The phrase “least intensive effective” is crucial. Over-placement can deplete benefit days, accelerate payer friction, and lead to early discharge when patients perceive a mismatch between the setting and their needs. Under-placement, conversely, can overlook acute risks and result in medical exits. Both scenarios ultimately manifest as increased discharge volume, rather than being identified as intake errors. This underscores the importance of measuring the level-of-care match rate at admission and auditing it against actual length of stay and discharge type.

Readiness assessment is another variable frequently under-measured by operators. Programs that rely solely on patient self-report at intake are working with highly unreliable data. The 2025 engagement review emphasizes that providers must proactively engage individuals and design services to increase retention, rather than passively waiting for motivation to emerge ¹⁶. Readiness is something the program actively cultivates within the first 72 hours, not a prerequisite the patient must possess upon arrival.

For this stage, the instrumentation question is whether the ASAM dimensions documented at intake accurately predict the assigned level of care, and whether that assignment correlates with a clinically appropriate completion. When the match rate declines, retention cannot be salvaged at later stages.

Building a Predictable Admissions Pipeline: Evidence-Based Approaches

Leverage research-driven content strategies that have demonstrated increased admissions consistency and reduced acquisition costs for treatment centers in competitive markets.

See Proven Methods

Stage Four: Retention Design

The Six-Month Reference Point and What Retention Actually Predicts

The FDA’s draft guidance for OUD device studies specifies a minimum treatment duration of six months and requires explicit plans for retention and handling missing data ⁷. While intended for clinical trials, this guidance provides a clear benchmark for what constitutes a serious retention window. Operators who only measure retention for 30 or 60 days are working with a shorter timeframe than the evidence base considers adequate.

Retention serves as a leading indicator, not the ultimate outcome. A 2022 analysis clarifies this limitation: treatment retention and adherence are moderately related to therapeutic success and should be complemented by other clinical and quality-of-life measures ¹⁰. Factors such as reduction in substance use, employment status, housing stability, and symptom improvement are equally important alongside length of stay. The FDA’s effectiveness guidance also recognizes the reduction in drug use patterns as a meaningful endpoint when linked to clinical benefit ⁶.

Operationally, programs should instrument retention at 30, 90, and 180 days as the key outputs of this stage. These rates should be paired with at least one clinical or functional measure that retention alone does not capture, providing a more comprehensive view of treatment success.

Barrier Reduction: Housing, Residential Placement, Phone Access, Mental Health

A CDC-hosted analysis of engagement following nonfatal overdose identifies specific services that predict patient retention in treatment. Housing assistance, residential treatment placement, consistent access to a phone, and mental health services were found to be particularly crucial for improving retention ¹¹. Each of these addresses a practical barrier that, if unaddressed, can lead to premature treatment termination.

The population data underscore the relevance of these barriers: in 2022, 17.7% of admissions were experiencing homelessness and 43.7% were unemployed ². A patient without stable housing may miss sessions due to logistical challenges, not lack of motivation. A patient without a working phone cannot receive appointment reminders. Untreated mental health comorbidities can precipitate relapse and subsequent discharge.

Programs that merely list these services as available, but route patients through case management queues that take a week to clear, are failing to operationalize their capabilities. The critical instrumentation question is whether each identified service is genuinely accessible within the first 72 hours of admission, measured by time-stamped referral and time-stamped service contact.

This also relates to the FDA’s caution regarding missing data in OUD device studies, which notes that maximizing participant retention is critical and missing data introduces significant uncertainty ⁸. The same principle applies internally: patients lost to follow-up due to unaddressed practical barriers prevent the program from accurately assessing its true outcomes.

Peer Support as Pipeline Infrastructure, Not an Add-On

Peer support staff bridge the gap between clinical structure and the lived experience of navigating recovery. A primary-care integration study describes their concrete role: peers provide education, empathy, coping skills, recovery modeling, and practical assistance in overcoming retention barriers ¹⁴. This practical assistance—addressing appointment scheduling, transportation, and benefits navigation—is often handled slowly by case managers or not at all by clinicians.

The role of peers has also expanded upstream into initial contact settings. A 2024 article highlights the increasing use of peers in emergency departments to connect individuals with OUD to care ¹⁵. For treatment centers receiving ED referrals, this means a “warm handoff” may already be in progress before the patient even contacts intake. The program’s ability to receive this handoff with same-day capacity determines whether the linkage holds.

Treating peer support as an optional enrichment service rather than essential pipeline infrastructure misunderstands its proven value. Peers are integral to how the four-stage system retains patients beyond the early drop-off window. Programs should measure peer caseload, the time from admission to the first peer contact, and compare the retention rates of peer-attached patients against those who are not.

Display the documented telehealth vs non-telehealth 90-day retention rates from the Kentucky and Ohio Medicaid study, which is directly cited and discussed in this section's context and the cost-per-retained-admission section

Reframing the Unit Economics: Cost Per Retained Admission

Focusing solely on “cost per admission” (CPA) is an incomplete metric. An admission that results in discharge after only 10 days incurs the same acquisition cost as one that completes a six-month episode, yet it yields a significantly smaller clinical and financial return. The FDA’s draft guidance for OUD device studies considers six months as the minimum treatment duration for meaningful measurement, emphasizing retention and accounting for missing data ⁷. This six-month window serves as a valuable reference point for operators, compelling them to evaluate what an admission truly delivers.

The shift in calculation is straightforward: if CPA represents the marketing cost to acquire one admission, the effective cost per retained admission is CPA divided by the retention rate at a program-defined meaningful window. For example, a program with a 90-day retention rate of 44% is effectively paying approximately 2.27 times its CPA for each patient still in care at that point. In contrast, a program with 48% retention pays 2.08 times CPA—a smaller multiplier that applies to every admission, every month ³.

Scenario	90-day retention	Effective cost per retained admission
Non-telehealth induction (Kentucky Medicaid)	44%	CPA ÷ 0.44 ≈ 2.27 × CPA
Telehealth induction (Kentucky Medicaid)	48%	CPA ÷ 0.48 ≈ 2.08 × CPA
Non-telehealth induction (Ohio Medicaid)	28%	CPA ÷ 0.28 ≈ 3.57 × CPA
Telehealth induction (Ohio Medicaid)	32%	CPA ÷ 0.32 ≈ 3.13 × CPA

These retention figures are specific to buprenorphine initiation in two state Medicaid populations and should not be broadly generalized ³. However, the underlying principle is structural: even modest improvements in the retention denominator can impact unit economics more significantly than equivalent changes in the acquisition numerator, because each dollar of CPA is divided by a larger fraction of patients who remain in care.

While retention alone is not a complete outcome measure—as adherence and length of stay are only moderately correlated with therapeutic success ¹⁰—it is the correct financial denominator. Programs that only report CPA are measuring marketing efficiency. Programs that report cost per retained admission are measuring whether their pipeline effectively produces clinical episodes that justify the acquisition investment.

If Operators Run Multiple Sites: Variance Compounds

The framework discussed so far assumes a single facility. For operators managing a portfolio of two or more sites, the financial implications change significantly: variance across locations compounds rather than averages. For instance, a network reporting a blended 90-day retention figure of 42% might obscure a high-performing site at 48% and a struggling site at 32%—a spread similar to that observed in Kentucky and Ohio Medicaid populations ³. Such an aggregated number provides no actionable insight for leadership.

Each site must be individually instrumented for its days-to-admission, level-of-care match rate, and 30/90/180-day retention. The weakest-performing site effectively caps the return on marketing spend, as referrals directed there will incur a higher effective cost per retained admission. Operators who allocate paid acquisition equally across locations, without factoring in retention performance, are inadvertently subsidizing their lowest-performing sites with the pipeline generated by their highest-performing ones.

An Instrumentation Plan for Quarter-Over-Quarter Improvement

The effectiveness of any framework hinges on the dashboard that supports it. Programs that consistently improve admissions quarter over quarter typically share a focused instrumentation strategy: they track one or two controllable metrics per pipeline stage, review them on a fixed cadence, and segment variance by referral source, payer, and level of care.

For the access stage, the key metric is the referral-to-contact rate within 24 hours, tracked by source. SBIRT-style screening pathways only convert to admissions when the handoff is effectively completed ¹. At the intake stage, the median days-to-admission and its variance are crucial, given the strong evidence linking delays to early drop-off ⁹. For clinical fit, the level-of-care match rate, audited against length of stay and discharge type, is essential, following SAMHSA’s recommended entry sequence ¹⁷.

For retention, the measurement cadence shifts. Operators should report 30-, 90-, and 180-day rates, aligning with the six-month reference window used by the FDA for OUD treatment studies ⁷. These rates should be paired with at least one functional measure, as retention alone is only moderately correlated with therapeutic success ¹⁰. This comprehensive set of metrics should be reviewed quarterly, with efforts focused on improving the weakest stage first.

Infographic showing Percentage of 2022 treatment admissions experiencing homelessness — Percentage of 2022 treatment admissions experiencing homelessness

Frequently Asked Questions

What is the most important metric to track for consistent treatment admissions?

Median days-to-admission, segmented by referral source and payer, is crucial. Peer-reviewed evidence indicates that delayed treatment entry significantly reduces retention through the first four sessions ⁹. This metric is directly controllable by operators and has a clear link to downstream retention, unlike external factors such as payer rules or workforce availability.

How does telehealth induction affect admissions and retention?

Telehealth induction can improve both admissions and retention, provided it is implemented as a same-day pathway rather than just a listed option. A Medicaid study on buprenorphine initiation showed 90-day retention rates of 48% via telehealth versus 44% in-person in Kentucky, and 32% versus 28% in Ohio ³. These deltas apply specifically to OUD induction in Medicaid populations and should not be generalized to all levels of care.

Why should operators measure cost per retained admission instead of cost per admission?

An admission that ends after 10 days incurs the same acquisition cost as one that completes a six-month episode, but it yields a fraction of the clinical and financial return. Calculating the effective cost per retained admission by dividing CPA by the retention rate at a meaningful window provides a more accurate picture. The FDA considers six months as the minimum treatment duration for OUD studies ⁷.

Which barrier-reduction services have the strongest documented link to retention?

A CDC analysis of engagement after nonfatal overdose identified four key services: housing assistance, residential treatment placement, consistent access to a phone, and mental health services ¹¹. These address practical barriers that commonly lead to early treatment termination. The operational test is whether these services are accessible within 72 hours of admission, not merely whether they are offered.

Where does peer support fit in the admissions pipeline?

Peer support is valuable at both the initial contact and retention stages. Peers offer education, empathy, coping skills, recovery modeling, and practical help in overcoming retention barriers ¹⁴. They are also increasingly deployed in emergency departments to connect individuals with OUD to care before they reach intake ¹⁵. Operators should measure the time from admission to first peer contact and compare retention rates between peer-attached and unattached patients.

What retention window should operators use as a benchmark?

A six-month window, with interim checkpoints at 30 and 90 days, is recommended. The FDA’s draft guidance for OUD device studies sets a minimum treatment duration of six months and requires explicit plans for retention and managing missing data ⁷. Retention should also be paired with at least one functional measure, as retention alone is only moderately correlated with therapeutic success ¹⁰.

References

SBIRT: Screening, Brief Intervention, and Referral to Treatment. https://www.samhsa.gov/substance-use/treatment/sbirt
Treatment Episode Data Set (TEDS) 2022: Admissions to and Discharges from Substance Use Treatment Services Reported by Single State Agencies. https://www.samhsa.gov/data/sites/default/files/reports/rpt53160/2022-teds-annual-report.pdf
Telehealth supports retention in treatment for opioid use disorder. https://nida.nih.gov/news-events/news-releases/2023/10/telehealth-supports-retention-in-treatment-for-opioid-use-disorder
Strategies for Expanding Access to Treatment for Opioid Use Disorder in High-Need Areas. https://www.medicaid.gov/medicaid/benefits/downloads/bhs/cmcs-fac-sht-str-for-exp-acc-to-tre-opioid-use-dis-high-need-area.pdf
Mandatory Medicaid State Plan Coverage of Medication-Assisted Treatment for Opioid Use Disorders. https://www.medicaid.gov/federal-policy-guidance/downloads/sho20005.pdf
Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment. https://www.fda.gov/media/114948/download
Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder. https://www.fda.gov/media/170561/download
Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder. https://www.fda.gov/media/171950/download
Days to Treatment and Early Retention Among Patients in Treatment for Alcohol and Drug Disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC3070832/
Retention in treatment and therapeutic adherence. https://pmc.ncbi.nlm.nih.gov/articles/PMC9720222/
Barriers to Engagement in Opioid Use Disorder Treatment After Nonfatal Overdose. https://stacks.cdc.gov/view/cdc/121741/cdc_121741_DS1.pdf
Outcomes for patients receiving telemedicine-delivered medication treatment for opioid use disorder. https://pmc.ncbi.nlm.nih.gov/articles/PMC7861202/
Telemedicine-delivered treatment for substance use disorder. https://pmc.ncbi.nlm.nih.gov/articles/PMC11444076/
Integrating peer support services into primary care-based OUD treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC9933784/
Peer support for patients with opioid use disorder in the emergency department. https://pmc.ncbi.nlm.nih.gov/articles/PMC11322658/
Clinical Considerations for Engagement and Retention of Patients with Substance Use Disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC12479062/
Chapter 5. Treatment Entry and Engagement. https://www.ncbi.nlm.nih.gov/books/NBK64084/